Hims & Hers因减重订阅信用卡争议被Visa纳入监控，收盘后不追空

Shares of consumer telehealth platform Hims & Hers Health (HIMS) tumbled just over 8% on Monday, pulling back from a strong recent run that had seen the stock climb more than 20% over the prior five sessions.
Late Friday, reports surfaced that Visa was set to impose penalties of nearly $75,000 on HIMS in September after thousands of credit card dispute complaints tied to weight-loss subscriptions triggered the company's inclusion in Visa's Acquirer Monitoring Program. Read more
HIMS finished Monday's session at $31.08, down $2.70 on the day. The stock had risen in the previous three sessions, including a jump of almost 14% on August 19
52-Week High: $65.30, more than double the current price
52-Week Low: $13.74, roughly 56% below the current price
50-Day SMA: $32.03 — last price is approximately 5.5% above this level
200-Day SMA: $28.89 — last price is approximately 17% above this level
RSI (14-Day): 58.13 — neutral-to-mild bullish momentum, not yet in overbought territory
Short Interest (% of Shares Outstanding): 27.66%
Volume: ~11.6 million shares (0.72x one-month average daily volume)
Other Recent News: Hims & Hers Health
August 18, 2026: CEO Andrew Dudum told CNBC he expects GLP-1 drug prices to eventually fall to $40-$50 per month from the current $150-$200 range, while defending the company against the FTC lawsuit and outlining plans to become "AI native" with proprietary models. Read more
August 10, 2026: HIMS reported Q2 GAAP EPS of -$0.37, missing estimates by $0.32, on revenue of $753.21M, a 38.3% year-over-year increase that beat consensus by $23.09M. Subscribers grew 19% year-over-year to approximately 2.9 million, and revenue per customer rose 21% to $92. Gross margin declined to 64% from 76% a year earlier, and operating expenses rose 48% to roughly $578M. The company guided Q3 revenue to $880M-$900M and raised full-year 2026 guidance to $3.1B-$3.3B. Read more.
August 3, 2026: A healthcare short-interest survey ranked HIMS as the second-most-shorted mid-to-mega-cap healthcare stock at 27.53% of shares outstanding, trailing only Tango Therapeutics. Read more
July 29, 2026: HIMS dropped after the FTC, alongside Los Angeles County and the Utah Department of Commerce, filed a lawsuit alleging the company shared users' health data with advertisers including Meta and Snap, made subscription cancellations difficult, and charged for unwanted refills. HIMS denied the allegations, calling the action "an effort to generate headlines." Read more
Latest Analyst Commentary on Hims & Hers Health
Cyn Research (August 19, 2026): Rated HIMS a Buy, citing 17-fold year-over-year international revenue growth to $131M aided by the Eucalyptus acquisition, AI investment aimed at reducing support costs, and scaling testosterone therapy as the company's next $100M+ specialty. Read more
Christopher Leder (August 18, 2026): Rated HIMS a Hold, noting the current price exceeds an implied fair value of $22 per share; while Q2 revenue rose 38% year-over-year, profitability was pressured by international expansion and restructuring costs. Read more
The Techie (August 14, 2026): Maintained a Buy rating, arguing HIMS's forward EV/Sales of 2.4x and forward Price/Sales of 2.18x remain below sector medians, with peptide manufacturing seen as a path to reducing partner dependency. Read more
Sharon McArd (August 12, 2026): Rated HIMS a Sell, arguing the raised guidance doesn't offset declining gross margins and negative free cash flow, with valuation at 24x adjusted EBITDA leaving little cushion given ongoing legal risks. Read more
Stone Fox Capital (July 30, 2026): Rated HIMS a Strong Buy, calling the FTC lawsuit selloff a buying opportunity given prior telehealth settlement precedents such as GoodRx and BetterHelp, and citing the Eucalyptus deal's expected $200M+ revenue contribution in the second half of 2026. Read more
Gene Chan, CFA (July 28, 2026): Rated HIMS a Buy, describing an "AI flywheel" built on closed-loop patient data and noting an FDA advisory panel's recommendation to add six of seven peptides to the compounding "Bulk List," pending final approval. Read more
What SA Users Are Saying About Hims & Hers Health
Sentiment across recent Seeking Alpha user comments is mixed-to-cautiously bullish, with several readers framing the margin compression and FTC lawsuit as overreactions while others flag balance-sheet and profitability concerns.
One SA user argued that HIMS "beat, guided up $300M (mostly due to Eucalyptus)" and that the stock's decline reflects "an odd obsession with adj. EBITDA margins," suggesting the path remains higher now that the GLP-1 compounding situation has resolved. Read more
Another commenter pointed to the revenue beat and subscriber additions as evidence that HIMS "really didn't miss," even as gross margins declined following the company's shift toward GLP-1 distribution. Read more
One reader expressed confidence that peptides will ultimately prove a winner for the company, while acknowledging margin pressure from low-priced GLP-1s following Novo's pricing shift. Read more
A separate SA user described the stock as being on a personal "do not trade" list, citing a pattern of negative headlines, many of them self-inflicted. Read more
One SA community member raised balance-sheet concerns, noting that while current assets rose by $600M, current liabilities climbed by $1.1 billion alongside $175M in six-month losses. Read more